Tremfya is a prescription drug used for psoriasis and psoriatic arthritis. Find out about possible interactions with alcohol, ...

The mucocutaneous and articular clinical phenotype is the most common presentation of Behçet’s disease (BD).1 Current ...

Some patients with psoriasis who were treated with guselkumab and achieved complete skin clearance experienced a persistent impact on quality of life.

Endoscopic remission and improvement in addition to maintenance of histological remission in ulcerative colitis is best achieved with upadacitinib.

Tremfya is now approved for the treatment of plaque psoriasis, active psoriatic arthritis and ulcerative colitis.

The FDA has approved Tremfya® (guselkumab) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).

The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for the treatment of adults with moderately to ...

Johnson & Johnson (NYSE: JNJ) has announced the FDA‘s approval of TREMFYA® (guselkumab) for adults with moderately to ...

US FDA approves Johnson & Johnson’s Tremfya for adults with moderately to severely active ulcerative colitis: Horsham, Pennsylvania Friday, September 13, 2024, 12:00 Hrs [IST] J ...

Approval of the dual-acting interleukin (IL)-23 inhibitor in ulcerative colitis was based on findings from QUASAR, an ongoing ...

Johnson & Johnson JNJ announced that the FDA approved its blockbuster immunology medicine, Tremfya (guselkumab), for a third ...